Business
Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome
Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n \n \n Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome\n \n \nEndonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome\n \n LOS ANGELES, CA--(Marketwired - Jun 29, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), a developer of bioelectronic devices and medicines, announced today that it has filed a continuation patent, titled \"Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells.\" Endonovo's patent filing covers a process for the production of the adult stem cell secretome and its corresponding administration as a next generation fully human biologic. \n This patent filing is a continuation of the prior announcement on March 30, 2016.\n Adult stem cells, such as Mesenchymal Stem Cells (\"MSCs\") isolated from tissues, including bone marrow and the human umbilical cord release a plethora of cytokines, interleukins, prostaglandins, and growth factors, referred to collectively as the secretome. \n Many studies have ascertained and continue to clarify that the therapeutic potential of adult stem cells is linked to their ability to secrete therapeutic proteins and other molecules. However, human cells typically secrete very low concentrations of these therapeutic cytokines and growth factors and have required the use of recombinant DNA technology to develop them as biologics.\n According to Thomson Reuters, the biologics sector is set for an unprecedented level of activity as U.S. companies have rapidly increased their development of biologics during the past five years. The market for next-generation biologics is estimated to reach a value of $30 billion by 2024, according to Visiongain. These next-generation biologics will seek to address shortcomings in current therapies, including inconvenient dosing and potential side-effects. \n Endonovo CEO, Alan Collier commented, \"We are largely looking at adult stem cells as tiny drug factories capable of producing the most complex and hard to produce drugs known as biologics.\" \n Mr. Collier went on to say, \"One of the benefits of our approach in using the secretome as a next generation fully human biologic is that it is much easier to manufacture than conventional biologics manufactured by synthetic or recombinant DNA technology, which could...